Clinical Trials Browser

OTHER × avelumab × Genitourinary × Clear all

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT04004442 2026-03-13

COAXIN

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT03252938 2026-02-19

INSIGHT

Phase 1 Active not recruiting

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05327686 2026-01-14

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT07110038 2026-01-12

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Phase 2 Active not recruiting

Neoplasm Metastasis, Penile Neoplasms

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Phase 1 Completed

Carcinoma, Transitional Cell

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Carcinoma, Renal Cell

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Urinary Bladder Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT06892860 2025-03-25

DISCUS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03674424 2025-02-26

AURA

Phase 2 Completed

Non-metastatic Muscle Invasive Bladder Cancer

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT04637594 2025-01-15

IMAGINE

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Phase 2 Withdrawn

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT03200587 2024-07-03

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Phase 1 Completed

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03892642 2024-02-14

OU-SCC-ABC

Phase 1/2 Completed

18 enrolled 15 charts

Urinary Bladder Neoplasms

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Unknown

Muscle Invasive Bladder Urothelial Carcinoma

NCT03390595 2023-10-18

INDUCOMAIN

Phase 2 Completed

Carcinoma, Transitional Cell

NCT05600127 2023-09-08

CHASIT

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT03774901 2023-04-21

PULSE

Phase 2 Unknown

Penile Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03502681 2022-07-01

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Phase 1 Terminated

6 enrolled 12 charts

Metastatic Urothelial Cell Cancer

NCT03324282 2022-05-03

GCISAVE

Phase 2 Terminated

Urinary Bladder Neoplasms

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03179410 2021-03-05

PICK-NEPC

Phase 2 Completed

15 enrolled 12 charts

Prostatic Neoplasms

NCT03498196 2020-08-24

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Phase 1/2 Terminated

1 enrolled 10 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03950362 2019-05-16

PREVERT

Phase 2 Unknown

Non-Muscle Invasive Bladder Neoplasms

NCT03341845 2018-05-21

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Phase 2 Unknown

Carcinoma, Renal Cell